HUTCHMED (China) (HCM) News
NASDAQ: HCMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.10+0.43 (+3.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
HCM news summary
We found 2 recent headlines mentioning HUTCHMED (China) (HCM): 0 in the past week and 1 in the past 30 days, most often from Nasdaq. For price context, HCM is up 3.15% at $14.10. The most recent story, "HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors", was published by Nasdaq on Sep 27, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest HUTCHMED (China) headlines
- HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors(RTTNews) - HUTCHMED (China) Limited (HCM) on Monday announced the initiation of the Phase 1a portion of a global clinical trial evaluating HMPL-A830 in patients with unresectable, advanced or…NasdaqGSK, HCM
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB